Author name: DrugChatter

Spend enough time in the DrugChatter logs and a pattern emerges. It’s not pharmacology. It’s not even really medicine. It’s […]

If you want to understand a drug, don’t start with the label—start with the questions people ask at 2 a.m.

There’s a particular genre of drug question that never goes out of style: “What happens if I mess this up?”

There’s a pattern to mass adoption in pharma. First comes clinical data, then prescriber uptake, then—inevitably—the public internet asking the

While DrugChatter is a specialized platform for medication discussions, many of the most surprising side effects surfaced by its users

Every morning, thousands of pharmaceutical field reps walk into physician offices carrying approved messaging, printed leave-behinds, and CRM notes from

Summary:Patient interest clusters heavily around drug–drug interactions, food effects, and therapeutic alternatives. Statins (especially Lipitor), biologics like Cosentyx, and common

By the time your next drug launches, a chatbot will already have an opinion about it — and 40 million

Why Pharmaceutical Companies Must Monitor AI Mentions Right Now There is a new drug representative calling on your patients and

How pharmaceutical brands are losing control of their narrative to AI answer engines — and the monitoring infrastructure they need

The Question Every Pharma Brand Team Is Ignoring Somewhere right now, a 54-year-old with newly diagnosed Type 2 diabetes is

What pharma’s regulatory, medical affairs, and brand teams need to do right now There is a scenario playing out across